NVEC

NVE Corporation (NVEC) - 10-K Summary

Business Context and Reporting Period

Company: NVE Corporation
Filing Type: Form 10-K (Annual Report)
Period Ended: March 31, 2017
Business Overview: NVE develops and sells spintronic devices (sensors, couplers, and MRAM technology) used to acquire, store, and transmit information. The company operates in a single segment serving commercial and military markets, with a significant portion of revenue derived from medical device manufacturers and factory automation sectors.

Key Financial Metrics

Note: The company maintains a debt-free balance sheet. Cash and marketable securities represented approximately 81% of total assets as of March 31, 2017.

Material Changes vs. Prior Period

• Revenue Growth: Total revenue increased 2.2% year-over-year to $28.3 million. This was driven by a 7.3% increase in product sales due to new customers, partially offset by a 35.2% decline in contract research and development (R&D) revenue due to the completion of specific contracts.
• Profitability: Net income rose 5.3% to $12.9 million. Gross profit margin improved to 78.5% from 76.1% in the prior year, attributed to a more profitable revenue mix.
• Expenses: Total operating expenses remained relatively flat. Research and development expenses increased 9.2% due to new product development, while selling, general, and administrative (SG&A) expenses decreased 16.8% primarily due to lower sales commissions.
• Backlog: Firm contract R&D backlog decreased significantly to $886,156 from $2.1 million in the prior year.

Outlook, Risks, and Management Commentary

Dividends and Capital Allocation: The company declared a quarterly dividend of $1.00 per share (totaling $4.00 for the fiscal year). Dividends are funded by operating cash flow and maturities of marketable securities. The Board has authorized a stock repurchase program with $4.54 million remaining, though no shares were repurchased in fiscal 2017.

Risk Factors:

• Customer Concentration: The company relies heavily on a few large customers. The two largest customers accounted for 42% of total revenue in fiscal 2017 (22% and 20% respectively). Loss of these customers could materially impact results.
• Supply Chain: Dependence on single-source suppliers for critical raw silicon wafers and packaging services poses a risk to production continuity.
• Investment Risk: With $76.4 million in marketable securities (81% of assets), the company is exposed to credit risk and market fluctuations. Some securities have been downgraded, though no other-than-temporary impairments were recorded.
• Product Liability: Products are used in medical devices (e.g., pacemakers), exposing the company to potential liability claims if products malfunction.

Guidance: The filing does not provide specific numerical guidance for fiscal 2018. Management expects foreign sales to continue representing a significant portion of revenue (52% in 2017) and anticipates working capital and cash from operations will be adequate through fiscal 2018.

Investor Verification Checklist

• Customer Concentration: Verify the stability of relationships with the top two customers (Abbott Laboratories and Sonova AG), which collectively drive over 40% of revenue.
• Dividend Sustainability: Assess whether the $4.00 per share annual dividend is sustainable given the depletion of marketable securities and the reliance on operating cash flow.
• Investment Portfolio Quality: Review the credit ratings of the $76.4 million marketable securities portfolio, noting that some have been downgraded by Moody's or S&P.
• R&D Pipeline: Evaluate the progress of new product initiatives (e.g., "smart sensors," biosensors) to replace the declining contract R&D revenue stream.
• Supply Chain Resilience: Confirm the status of single-source wafer and packaging suppliers to ensure no disruptions to manufacturing.